November 4, 2015 - ZOLL Technology for Improving CPR Quality to Be Showcased at American Heart Association Annual Conference

CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

 

 

ZOLL TECHNOLOGY FOR IMPROVING CPR QUALITY TO BE SHOWCASED AT AMERICAN HEART ASSOCIATION ANNUAL CONFERENCE

Fourteen Scientific Presentations Related to ZOLL Technologies Scheduled at ReSS

November 4, 2015—CHELMSFORD, MASS.—ZOLL® Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, announced today its fully integrated portfolio of resuscitation devices and data management solutions that are uniquely capable of helping customers achieve the new recommendations of the 2015 AHA Guidelines, will be on display during the American Heart Association (AHA) 2015 Annual Conference in Booth 745 November 8-10 in Orlando.

Increasing the quality of CPR has been an ongoing commitment of ZOLL’s since 2002, when it was the first to introduce real-time CPR feedback in its AED Plus®. Today, all ZOLL defibrillators, including the AED Plus, the AED Pro®, the R Series®, and the X Series®, feature Real CPR Help® audio and visual feedback for the correct rate, depth, release, and tracking of idle time. Real CPR Help is the only CPR-feedback technology that, in combination with training, has been shown to impact survival to discharge, as demonstrated in published research.1

ZOLL’s commitment to high-quality CPR is also evident in the company’s suite of tools for optimal resuscitation response, which includes See-Thru CPR® as well as EtCO2 monitoring. See-Thru CPR, ZOLL’s proprietary technology which minimizes the duration of pauses in CPR by enabling rescuers to see an organized, underlying rhythm, is available on the R Series, the X Series, and the AED Pro.

Additionally, the 2015 Guidelines recommend automated CPR devices, such as the AutoPulse® Resuscitation System, as Class IIb, citing their role in performing high-quality CPR when manual CPR is difficult to achieve, such as during patient transport or in the cath lab. ZOLL’s new ResQCPR® System, the first and only CPR device indicated to improve survival from sudden cardiac arrest, was also recommended as Class IIb.

The new Guidelines expand the recommendation for post ROSC cooling to include all comatose patients, regardless of rhythm or location of arrest. ZOLL’s Thermogard XP® Temperature Management System is uniquely capable of helping hospitals achieve precise temperature control for any recommended target between 32°C and 36°C.

Also unique to ZOLL is the LifeVest® Wearable Defibrillator, which is worn by patients at risk for sudden cardiac death (SCD), providing protection during their changing condition and while permanent SCD risk has not been established. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm. The LifeVest is lightweight and easy to wear, and allows a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.

New to ZOLL’s expanding product portfolio is the Eagle II portable critical care ventilator, which is used in the management of patients ≥5 kg with acute or chronic respiratory failure. It can be used inside the hospital, during transport and in MRI suites. The Eagle II is designed to be durable and lightweight with a 10-hour battery, and multiple modes of ventilation including non-invasive ventilation.

Scientific Assembly Presentations

An education grant from ZOLL helps to underwrite the AHA Resuscitation Science Symposium (ReSS), an international forum for scientists and care providers to discuss recent advances related to treating cardiopulmonary arrest and life-threatening traumatic injury. Fourteen scientific presentations related to ZOLL products and technology are scheduled to be presented during ReSS. Key presentations are:

  • Norman Paradis, MD, will present “The Detrimental Effect of Chest Compression Interruptions on Coronary Perfusion Pressure Dynamics,” Sunday, November 7 at 1:00-2:30 p.m. in the Valencia Ballroom W415CD. Poster 135.
  • Taro Irisawa, MD, will present “Maintaining High Quality CPR with an Integrated Manual/Mechanical Resuscitation Protocol,” Sunday, November 7 at 1:00-2:30 p.m. in the Valencia Ballroom W415CD. Poster 136.
  • Yoshiaki Mitsutake, MD, will present “Pre-reperfusion Rapid Endovascular Hypothermia Exhibits a Strong Dose-dependent Reduction in Infarct Size in a Porcine Ischemia Reperfusion Model,” Sunday, November 7 at 5:30-6:45 p.m. in W311EF. Oral 17993.
  • Chingping Wan, MD, ZOLL, will present “Use of a Wearable Cardioverter Defibrillator (WCD) to Protect Patients After ICD Explanation: Results From the National Registry,” Tuesday, November 10 at 9:00-10:15 a.m. in Room A2. Poster T4067.
  • Nicole R. Bianco, PhD, ZOLL, will present “The Effect of Internal vs. External Shocks on Myocardial Injury in an Animal Model of Myocardial Infarction,” Tuesday, November 10, 9-10:15 a.m. in Room A2. Poster T 4065.

A listing and schedule of the ZOLL-related presentations is available at http://www.zoll.com/aha-presentations2015/.

About ZOLL Medical Corporation

ZOLL Medical Corporation, an Asahi Kasei Group Company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, therapeutic temperature management, and ventilation. ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.

About Asahi Kasei

The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 30,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.

11Bobrow BJ, et al. Ann Emerg Med. 2013 Jul;62(1):47–56.e1. Epub 2013 Mar 7.

Copyright © 2015 ZOLL Medical Corporation. All rights reserved. AED Plus, AED Pro, AutoPulse, Eagle II, LifeVest, R Series, Real CPR Help, See-Thru CPR, Thermogard XP, X Series, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All other trademarks are the property of their respective owners.